Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (BEIGF) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for BeOne Medicines (BEIGF) over the last 11 years, with Q3 2025 value amounting to $354.5 million.

  • BeOne Medicines' Free Cash Flow rose 54785.8% to $354.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $544.6 million, marking a year-over-year increase of 15475.69%. This contributed to the annual value of -$633.3 million for FY2024, which is 6316.66% up from last year.
  • BeOne Medicines' Free Cash Flow amounted to $354.5 million in Q3 2025, which was up 54785.8% from $223.4 million recorded in Q2 2025.
  • BeOne Medicines' Free Cash Flow's 5-year high stood at $354.5 million during Q3 2025, with a 5-year trough of -$689.4 million in Q1 2023.
  • Moreover, its 5-year median value for Free Cash Flow was -$299.3 million (2022), whereas its average is -$238.9 million.
  • In the last 5 years, BeOne Medicines' Free Cash Flow plummeted by 372873.77% in 2022 and then soared by 54785.8% in 2025.
  • Over the past 5 years, BeOne Medicines' Free Cash Flow (Quarter) stood at $12.1 million in 2021, then tumbled by 3728.74% to -$439.5 million in 2022, then rose by 13.87% to -$378.6 million in 2023, then soared by 95.43% to -$17.3 million in 2024, then soared by 2146.59% to $354.5 million in 2025.
  • Its Free Cash Flow stands at $354.5 million for Q3 2025, versus $223.4 million for Q2 2025 and -$15.9 million for Q1 2025.